Global Focus on Improved Outcomes: Global Complex Regional Pain Syndrome (CRPS) Market
The global demand for complex regional pain syndrome market is poised for significant growth in the coming decade. With an estimated worth of USD103.7 million in 2023, the market is forecasted to expand at a compound annual growth rate (CAGR) of 2.2% during the projection period from 2023 to 2033.
The latest analysis report by FMI underscores the positive trajectory of the CRPS market, predicting it to reach USD129.2 million by 2033. This growth is driven by increasing awareness, advancements in treatment options, and a growing patient population seeking effective therapies for CRPS.
The increase in the number of individuals suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the main drivers of market expansion. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect a person’s entire body or only their hands, feet, arms, and legs.
Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1708
As healthcare professionals and researchers continue to explore new approaches to managing CRPS, the market is expected to witness sustained expansion, offering hope for improved outcomes and quality of life for patients worldwide.
Both of the two forms of CRPS have the same symptoms and available treatments. Complex Regional Pain Syndrome (CRPS) Type I, sometimes referred to as reflex sympathetic dystrophy, appears following an injury without any nerve damage. Type II CRPS may occur as a result of specific nerve injury or trauma.
Key Takeaways:
The global complex regional pain syndrome (CRPS) market is estimated to reach USD129.2 million by 2033, reflecting a rise from USD103.7 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 2.2% throughout the forecast period.
The rising prevalence of CRPS and chronic pain conditions are key drivers for market expansion
Market Competition:
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company’s New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.
Key Companies Profiled:
Mallinckrodt Pharmaceuticals
GlaxoSmithKline plc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
AbbVie
ACTAVIS
Zydus Pharmaceuticals Inc.
Sandoz
Janssen Global Services LLC.
Medline Plus
Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey:
By Therapy Type:
Physical Therapy
Therapy via Drugs
Analgesics
Antidepressants
Corticosteroids
Others
Surgical Sympathectomy
Intrathecal Drug Pumps
Spinal Cord Stimulation
By Route of Administration:
Oral Therapy
Intravenous Therapy
By Distribution Channel:
Hospital Pharmacy
Drug Stores
Retail Pharmacy
E-Commerce
By Region:
North America
Latin America
Europe Complex
Asia Pacific
The Middle East and Africa
Global Focus on Improved Outcomes: Global Complex Regional Pain Syndrome (CRPS) Market
The global demand for complex regional pain syndrome market is poised for significant growth in the coming decade. With an estimated worth of USD103.7 million in 2023, the market is forecasted to expand at a compound annual growth rate (CAGR) of 2.2% during the projection period from 2023 to 2033.
The latest analysis report by FMI underscores the positive trajectory of the CRPS market, predicting it to reach USD129.2 million by 2033. This growth is driven by increasing awareness, advancements in treatment options, and a growing patient population seeking effective therapies for CRPS.
The increase in the number of individuals suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the main drivers of market expansion. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect a person’s entire body or only their hands, feet, arms, and legs.
Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1708
As healthcare professionals and researchers continue to explore new approaches to managing CRPS, the market is expected to witness sustained expansion, offering hope for improved outcomes and quality of life for patients worldwide.
Both of the two forms of CRPS have the same symptoms and available treatments. Complex Regional Pain Syndrome (CRPS) Type I, sometimes referred to as reflex sympathetic dystrophy, appears following an injury without any nerve damage. Type II CRPS may occur as a result of specific nerve injury or trauma.
Key Takeaways:
The global complex regional pain syndrome (CRPS) market is estimated to reach USD129.2 million by 2033, reflecting a rise from USD103.7 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 2.2% throughout the forecast period.
The rising prevalence of CRPS and chronic pain conditions are key drivers for market expansion
Market Competition:
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company’s New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.
Key Companies Profiled:
Mallinckrodt Pharmaceuticals
GlaxoSmithKline plc.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
AbbVie
ACTAVIS
Zydus Pharmaceuticals Inc.
Sandoz
Janssen Global Services LLC.
Medline Plus
Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey:
By Therapy Type:
Physical Therapy
Therapy via Drugs
Analgesics
Antidepressants
Corticosteroids
Others
Surgical Sympathectomy
Intrathecal Drug Pumps
Spinal Cord Stimulation
By Route of Administration:
Oral Therapy
Intravenous Therapy
By Distribution Channel:
Hospital Pharmacy
Drug Stores
Retail Pharmacy
E-Commerce
By Region:
North America
Latin America
Europe Complex
Asia Pacific
The Middle East and Africa
French (Français)
Spanish (Español)
Arabic
Portuguese (Português)
Deutsch
Turkish (Türk)
Dutch (Nederlands)
Italiano
Romaian (Română)
Português (Brasil)
Greek (Ελληνικά)
Russian (русский)